Table 3.
Infection characteristics and treatment in heart transplanted patients.
| Parameters | All | mdr/xdr Infections |
Non-mdr/xdr
Infections |
p |
|---|---|---|---|---|
| Patients with any infectious episodes * | 35 (74.5) | 14 (40) | 21 (60) | 0.135 |
| Total infectious episodes, n | 58 | 24 | 34 | |
| Types of infectious episodes | ||||
| Pneumonia | 21 (36.2) | 10 (41.7) | 11 (32.3) | 0.577 |
| Bloodstream infection (BSI) | 10 (17.2) | 7 (29.2) | 3 (8.8) | 0.043 |
| Skin and soft tissue infection (SSTI) | 8 (13.8) | 6 (25) | 2 (5.9) | 0.047 |
| Complicated Urinary tract infection (cUTI) | 14 (24.1) | 1 (1.8) | 13 (38.2) | 0.002 |
| Mediastinitis | 4 (6.9) | 0 | 4 (11.8) | 0.072 |
| Unknown | 1(1.7) | 0 | 1 (3) | ns |
| SOFA score at the time of 1st infection onset | 7 (1–15) | 8 (4–13) | 4.5 (1–15) | 0.027 |
| days between ht and 1st isolation | 9.5 (0–54) | 10.5 (3–44) | 8.5 (0–54) | 0.408 |
| eradication of infectious episodes | 38 (65.5) | 13 (54.2) | 25 (78.1) ** | 0.083 |
| antibiotic therapy | ||||
| Amikacin | 1 (1.7) | 1 (4.1) | 0 | ns |
| Amoxicillin/clavulanic acid | 6 (10.3) | 1 (4.1) | 5 (14.7) | 0.366 |
| Aztreonam | 1 (1.7) | 1 (4.1) | 0 | ns |
| Cefazolin | 1 (1.7) | 0 | 1 (2.9) | ns |
| Cefepime | 5 (8.6) | 0 | 5 (14.7) | 0.049 |
| Cefixime | 1 (1.7) | 0 | 1 (2.9) | ns |
| Ceftazidime/avibactam | 2 (3.4) | 2 (8,2) | 0 | 0.153 |
| Ciprofloxacin | 2 (3.4) | 0 | 2 (5.8) | ns |
| Colistin aerosol | 4 (6.8) | 3 (12.3) | 1 (2.9) | ns |
| Colistin iv | 8 (13.7) | 6 (25) | 2 (2.9) | 0.039 |
| Cotrimoxazole | 8 (13.7) | 4 (16.4) | 4 (11.7) | ns |
| Daptomycin | 6 (5.1) | 5 (20.8) | 1 (2.9) | 0.017 |
| Ertapenem | 1 (1.7) | 1 (4.1) | 0 | ns |
| Gentamicin ev | 3 (5.1) | 3 (12.3) | 0 | ns |
| Levofloxacin | 4 (6.8) | 0 | 4 (11.7) | 0.082 |
| Meropenem | 9 (15.5) | 4 (16.4) | 5 (14.7) | ns |
| Piperacillin/tazobactam | 8 (13.7) | 3 (12.3) | 5 (14.7) | ns |
| Teicoplanin | 5 (8.6) | 0 | 5 (14.7) | 0.049 |
| Tigecycline | 2 (3.4) | 1 (4.1) | 1 (2.9) | ns |
| Duration of therapy, days | 10 (2–61) | 15.5 (3–61) | 7.5 (2–38) | 0.057 |
Data are expressed as median and interquartile range, or number and percentages; Abbreviations: iv, intravenous; MDR/XDR, multidrug-resistant/extensively drug-resistant; SOFA, Sequential Organ Failure Assessment; ns, non-significant. * Percentages in rows. ** Two patients without microbiological etiology excluded.